According to a recent LinkedIn post from Glooko, new CMS Inpatient Quality Reporting requirements now mandate hospitals to report electronic clinical quality measures for severe hypoglycemia and hyperglycemia. The post highlights a Becker’s Healthcare webinar featuring Glooko’s Paul Chidester, M.D., and clinical leaders from several major U.S. health systems discussing strategies to standardize inpatient glycemic care and comply with these guidelines.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests Glooko is positioning its expertise and solutions around glycemic management at a time when regulatory scrutiny on inpatient glucose control is increasing. For investors, this focus on CMS-driven quality metrics could signal growing demand for data-driven diabetes management tools in hospital settings, potentially expanding Glooko’s addressable market and strengthening its relationships with large health systems.
By associating with organizations such as NYC Health + Hospitals, Hackensack Meridian Health, and Temple Health, Glooko appears to be reinforcing its visibility among enterprise healthcare customers. If the company can translate this thought-leadership activity into product adoption or deeper integrations, it may enhance recurring revenue opportunities and support a more defensible competitive position in inpatient diabetes and glycemic management solutions.